Early trial testing treatments for COVID-19 in the first days
Treatments studied
Part of Infections, Lungs & breathing clinical trials.
This early-stage study tests COVID-19 treatments in people who have recently developed symptoms and who test positive for the virus. It aims to find safer, more effective options for preventing worsening disease, especially in higher-risk groups.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re an adult (age 18 or older) with confirmed COVID-19 by a lab test (PCR) or, in some parts of the study, a rapid test (lateral flow).
- You can sign consent yourself (or have a legal representative sign).
- You must not be pregnant or breast-feeding.
- If you can become pregnant, or you’re a man with a partner who can become pregnant, you must use reliable birth control exactly as the study requires during treatment and afterward.
- Your COVID-19 symptoms must have started within a short time window before the first dose (often within 5 days, depending on the group).
- You must be able to follow study visits and procedures for the first several weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an antiviral medicine called FS-1 (brand name Efesovir) in adults hospitalized with COVID-19 who have risk factors for severe illness. The goal is to see if the drug can help them recover faster or avoid more serious complications.
This early-phase study tests immune cells from a matched family donor (made to target the COVID-19 virus) to see if they can help people with mild-to-moderate COVID-19 who are hospitalized and at higher risk for getting sicker. It aims to check safety first and also look for signs of benefit.
This study tests a new antibody medicine for people with COVID-19 who are at high risk of getting very sick. If you qualify, you would receive the study drug or a placebo (inactive substance) to see if it helps you recover without needing to go to the hospital.
This trial looks at how well an antiviral works in the body when started early in people with COVID-19 symptoms. You may be able to join if you’re an otherwise healthy adult with confirmed infection and symptoms for less than 4 days.
This trial tests whether Codivir can help people hospitalized with moderate COVID-19 recover better than a placebo (inactive pill). It will compare outcomes while participants receive standard hospital care.
This early-phase trial tests a new drug (called B10-FC) to see if it's safe and how the body processes it. It is given once to healthy adults, and later to people with mild or moderate COVID-19 who are at higher risk of getting very sick.
Hear when a new Covid19 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.